elsewhere

Jinggou Biotech Closes Tens of Millions of Yuan in Series A Funding, Dalton Venture Bets on Synthetic Biology for Nutrition and Health | Dalton News

Recently, emerging Chinese synthetic biology company **Hangzhou Jinggou Biotechnology Co., Ltd. (hereinafter referred to as "Jinggou Bio") announced the completion of a Series A financing round worth tens of millions of RMB, with Dalton Venture participating in the investment.** Proceeds from this round will be primarily directed toward R&D investment and production base capacity building, accelerating the scaled production of high-value-added nutritional health and feed additive products, and advancing the commercialization of green bio-manufacturing.

道彤投资·2025年9月5日

China's First Batch! Astribot Secures Thousand-Unit AI Robot Order, Ushering in a New Chapter of Large-Scale Industrial Agent Deployment | Tong's Family

Recently, **Astribot, a member of the Datong Family**, announced a strategic partnership with SEER Intelligence for a thousand-unit humanoid robot order. Over the next two years, the two companies will drive the large-scale, phased deployment of over a thousand AI robots across industrial, manufacturing, warehousing, and logistics scenarios. This collaboration marks a new phase of "industrial intelligent agent" applications for AI robots, sets a benchmark for the commercialization of embodied intelligence technology, and represents a significant step in advancing "new quality productive forces."

道彤投资·2025年9月2日

"The Made-in-China" Breakthrough Moment: DaYi Group and Hanno Medical Featured in Xinhua News Agency Report | TongNews

On August 27, Xinhua News Agency published a special report titled *"More and More 'Made in China': China's Medical Equipment Achieves New Breakthroughs"*, comprehensively presenting the leapfrog development of China's medical equipment industry since the 14th Five-Year Plan period. In the report, **TAICHI Medical Systems** and **Hanano Medical**, two portfolio companies of **Dowstone Capital**, were specifically named, with their product innovation achievements drawing attention. This reflects not only the breakthrough capabilities of the enterprises themselves, but also the acceleration of China's medical equipment industry toward self-reliance and comprehensive —

道彤投资·2025年8月28日

Dalton Venture's Sun Qi: Focus, Steady Rhythm, Multiple Paths — Actively Positioning Through the Cycle | Dalton Insights

On July 3–4, 2025, **the 19th China Fund Partners Conference, co-hosted by Zero2IPO and PEDaily, was held in Shanghai**. This year's gathering brought together capital leaders to discuss industry trends, examine the latest dynamics in China's LP market, and explore the path forward for venture capital in a new cycle. **Dalton Venture founding and managing partner Sam Sun was invited to join the roundtable forum *"Cycle Positioning, Investment Strategies"*** to exchange views with fellow guests on the evolution of investment cycles and responsive strategies.

道彤投资·2025年7月8日

Aiyisheng Completes Angel Round with DaoTong as Sole Investor, Accelerating Clinical Trials for Small-Caliber Artificial Blood Vessels | DaoTong News

Recently, **Aison (Guangzhou) Biotech Co., Ltd.** (hereinafter referred to as Aison Medical) **announced the completion of its angel round, led exclusively by Dalton Venture.** The proceeds will be primarily used to advance the clinical development of small-diameter artificial blood vessels and to expand applications of its core technology.

道彤投资·2025年5月27日

How Does Dalton Venture Precisely Capture Investment Growth Opportunities by Focusing on Cardiovascular Disease Diagnosis, Treatment, and Management? | Dalton Insights

For decades, cardiovascular disease has been considered the "leading killer" threatening global human health and longevity, with mortality rates reaching 5% among patients over 65. As population aging accelerates and lifestyles shift, the prevalence of chronic heart conditions is rising markedly — spurring waves of innovation across cardiovascular device segments to address persistent treatment pain points and improve diagnostic and therapeutic efficiency and safety.

道彤投资·2025年5月26日

Riding the Wind, Breaking Boundaries — Tides Surge in Hong Kong | Dalton Venture 2025 CEO Summit Successfully Concludes

At the intersection of technological revolution and industrial transformation, what should be the starting point for the globalization of the life sciences industry? Where should mainland Chinese healthcare innovators set their first foothold for overseas expansion? Against a backdrop of intensifying international competition and sustained policy tailwinds, is Hong Kong — a city that blends international perspective with institutional advantages — emerging as the bridge for tech ventures to reach the world?

道彤投资·2025年4月28日

Heyuan Medical Closes Funding Round Exceeding RMB 100 Million, Dalton Venture Co-Leads Investment, Multiple Breakthrough Technologies Empower Heart Failure Management | Dalton Venture News

Recently, **Shanghai-based United InnoMed® announced the completion of a new funding round exceeding 100 million RMB**. The round was **jointly led by Dalton Venture and Dragonstone Capital**, with follow-on investments from Yinglian Health Fund and Tianrui Fengnian Capital. Existing investor Lilly Asia Ventures continued to increase its stake. **The proceeds will be primarily used for the R&D and registration clinical trials of multiple core pipeline products.**

道彤投资·2025年4月22日

Yuantian Biotechnology Closes Nearly 100 Million Yuan Pre-A+ Round, Dalton Venture Bets on Enzymatic PET Recycling | Dalton News

Recently, **Yuantian Biotechnology (Tianjin) Co., Ltd. (hereinafter referred to as "Yuantian Bio") announced the completion of a nearly 100 million yuan Pre-A+ funding round, with Dalton Venture participating in this round** to support the company's kiloton-scale production line construction, product technology advancement, and market expansion.

道彤投资·2025年4月16日

Dalton Venture's Sun Qi: Building Confidence Through Cyclical Swings, Riding Out Industry Ups and Downs | Dalton Insights

As winter fades and spring arrives, China's venture capital industry's annual opening gala convened as scheduled. On February 28, 2025, the "PEDaily 100" hosted by Zero2IPO and PEDaily took place in Sanya, bringing together the investment community to take the pulse of an unprecedented 2025. **Dalton Venture founding managing partner Sam Gao** was invited to participate in the roundtable discussion ***Healthcare Investment: Against the Current***, sharing Dalton Venture's positioning and thinking in the healthcare sector.

道彤投资·2025年3月18日

道彤投资

Articles